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Abstract
Background: The present study sought to investigate the association between HLA-A, HLA-B and HLA-DRB1 genes
and susceptibility or resistance to the different clinical manifestations of American cutaneous leishmaniasis (ACL) in
southern Brazil.
Methods: The sample consisted of 169 patients with a diagnosis of ACL and 270 healthy subjects for comparison.
HLA-A, HLA-B and HLA-DRB1 were typed by PCR-SSO reverse dot blot.
Results: Results showed a trend towards susceptibility to cutaneous lesions for alleles HLA-DRB1*13 (P=0.0228;
Pc=0.3420; OR=1.66; 95%CI=1.08 – 2.56), HLA-B*35 (P=0.0218; Pc=0.6758; OR=1.67; 95%CI=1.08 – 2.29) and HLA-B*44
(P=0.0290; Pc=0.8990; OR=1.67; 95%CI=1.05 – 2.64). Subjects with allele HLA-B*27 (P=0.0180; Pc=0.5580; OR=7.1111;
95%CI=1.7850 – 28.3286) tended towards susceptibility to mucocutaneous lesions, those with HLA-B*49 (P=0.0101;
Pc=0.3131; OR=6.4000; 95%CI=1.8472 – 22.1743) to recurrent ACL, and HLA-B*52 (P=0.0044; Pc=0.1360; OR=12.61;
95%CI=3.08 – 51.66), to re-infection. Presence of HLA-B*45 (P=0.0107; Pc=0.3317) tended to provide protection
against the cutaneous form of ACL. The most frequent haplotypes that may be associated with susceptibility to
ACL were A*02 B*44 DRB1*07 (P = 0.0236) and A*24 B*35 DRB1*01 (P = 0.0236).
Conclusion: Some Class I and Class II HLA genes appear to contribute towards susceptibility to and protection
against different clinical manifestations of ACL. Other genetic marker studies may contribute toward future
prophylactic and therapeutic interventions in ACL.
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Background
American cutaneous leishmaniasis (ACL) is a non-
contagious infectious disease, caused by several species of
protozoa in the genus Leishmania and transmitted by
sandfly bites, which causes skin and mucosal lesions [1-3].
In Brazil, ACL has been notified to the health author-
ities since the 1980s. Between 1990 and 2008, some
527,976 cases were notified, 12,115 of which in the
southern region of Brazil, with 11,557 cases (95.4%) from
the state of Paraná alone [4]. The northern and western
regions of the Southern state of Paraná stand out due to
their high concentration of ACL cases, and are thus con-
sidered areas of epidemiological importance [5]. In these
regions, the predominant species (98.7%) is Leishmania
(Viannia) braziliensis [6,7].
Infection by L. braziliensis may develop into the localized
clinical cutaneous and/or mucosal forms of ACL. Cure of
ACL is determined clinically, and is defined by regression
of lesions within three months of concluding therapy. Peri-
odical follow-up for 12 months is recommended. However,
relapse of the disease may occur during the first year after
cure. Relapse consists of the appearance of the cutaneous
lesion at its former site or recurrence of mucosal lesions
due to potential hematogenous spread of the infection [3].
It is estimated that relapse of cutaneous lesions occurs in
* Correspondence: sdborelli@uem.br
4Immunogenetics Laboratory, Department of Basic Health Sciences,
Universidade Estadual de Maringá (UEM), Av. Colombo, 5.790 - Jd.
Universitário, Maringá, Paraná 87020-900, Brazil
Full list of author information is available at the end of the article
© 2013 Ribas-Silva et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Ribas-Silva et al. BMC Infectious Diseases 2013, 13:198
http://www.biomedcentral.com/1471-2334/13/198
approximately 10% of infected patients, whereas mucocu-
taneous lesion relapse, which constitutes the most severe
complication of ACL, occurs in 4% of cases [8-11]. A dis-
tinct manifestation is recurrent ACL, which, unlike relapse,
consists of the onset of cutaneous lesions in places other
than those of the previous infection, possibly indicat-
ing reinfection [10].
The progression of ACL varies according to environ-
mental factors, vector characteristics, parasite genetics
and host immunological factors. Furthermore, patients
infected with the same Leishmania species may develop
different clinical forms of ACL even if they have the same
nutritional conditions and are exposed to the same envir-
onmental factors [12-15]. In certain studies, HLA alleles
have been associated with disease progression in cutane-
ous and mucocutaneous leishmaniasis [16-19]. In this
context, the conduction of studies related to host genetic
markers after exposure to the parasite is highly relevant.
Due to the dearth of data on genetic polymorphism of
the HLA system and its association with protection
against and/or susceptibility to development of ACL in
the Brazilian population, the present study investigated
possible involvements of Class I (HLA-A, HLA-B) and
Class II (HLA-DRB1) HLA genes in the different clinical
manifestations of ACL in populations of endemic re-




A retrospective study was carried out on the epidemio-
logical records of patients from the 13th and 15th Health
Sections of the state of Paraná diagnosed with ACL. The
diagnosis was made at the Leishmaniases Laboratory of
the State University of Maringá. Patients with clinical
manifestations of the disease and with positive parasite
detection and/or Montenegro skin test who received a
medical prescription for treatment two years ago were
selected. This period was defined because, according to
WHO, more than 90% of recurrent cases occur up to
one year after treatment.
Patient age at data collection ranged between 17 and
83 years (mean, 47.38 ± 14.79); 139 (82.3%) patients
were males and 30 (17.8%) were females. According to
ethnicity (skin color using Brazilian census categories),
patient groups consisted of 127 (75.2%) caucasian; 36
(21.3%) amerindians; 4 (2.4%) african and 2 (1.2%) asian.
The control group comprised 260 healthy subjects,
chosen according to age, gender, ethnicity, occupation
and other demographic parameters, who had visited
areas where ACL is endemic and had no clinical mani-
festations of the disease. Age ranged between 18 and
73 years (mean, 30.31 ± 10.92); 141 controls (54.2%)
were males and 119 (45.8%) were females. The ethnic
distribution was 208 (80.0%) white, 37 (14.2%) brown,
8 (3.1%) black and 7 (2.7%) yellow.
Research subjects were interviewed and information
was recorded in social-epidemiological files which in-
cluded notes on clinical manifestations occurring after
treatment, such as development of the mucosal form or
even relapse. All subjects were informed of the investiga-
tion, and those who agreed to allow use of their data
provided written informed consent. The study was ap-
proved by the Permanent Human Subject Research Eth-
ics Committee of the State University of Maringá, with
judgment number 153/2009.
Group composition
The study population comprised 169 subjects with a
positive diagnosis of ACL who had received therapy and
lived in Southern Brazil. The control group consisted of
260 subjects with no clinical manifestations of ACL who
lived in the same area from which patients were
recruited and who also frequented areas posing a high
risk of infection (shrubland with nearby streams). Sub-
jects belonging to both groups were unrelated.
According to clinical and laboratory data, patients
were allocated into 4 groups and 6 subgroups (Figure 1).
Group 1 comprised subjects who had a cutaneous
form of the disease and no evidence of any relapse. This
group was subdivided into Group 1A, composed of 118
individuals who had a positive parasitological diagnosis,
and Group 1B, composed of 18 individuals who had only
a positive Montenegro test.
Group 2 consisted of subjects with clinical manifesta-
tions of mucosal disease. This group was subdivided into
Group 2A, composed of 11 individuals with a positive
laboratory diagnosis (parasite survey and/or Montenegro
skin test) of a past cutaneous lesion with subsequent de-
velopment of a mucosal lesion, and Group 2B, compris-
ing 4 individuals who had a mucosal lesion but no
history of previous cutaneous lesions.
Group 3 comprised individuals who had the cutaneous
form of the disease and, after treatment, developed cuta-
neous lesions again. This group was subdivided into
Group 3A, composed of 11 individuals who had a positive
laboratory diagnosis (parasitological and/or Montenegro
skin test) and lesion relapse at the original site, and Group
3B, composed of 7 individuals who had a positive labora-
tory diagnosis (parasitological and/or Montenegro skin
test) and lesion relapse at a different site.
Group 4 comprised all subjects with a history of recur-
rent disease—Groups 2A and 3A. Recurrent ACL was de-
fined as the onset of a new lesion after at least 1 year of
treatment, whether at the same site of the previous lesion
(Group 3A) or, subsequently, in the mucosa (Group 2A).
The small number of individuals in certain groups and
subgroups of ACL was a limiting factor in this study,
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justified by the frequency of some clinical manifesta-
tions. Recurrence of ACL occurs in approximately 10%
of infected patients, and mucocutaneous lesion relapse
occurs in 4% of infected patients [8-11]. Thus, this study
demonstrates the preliminary results of these groups.
Determination of HLA alleles
Peripheral blood samples (10 mL) were collected from
patients and controls into EDTA anticoagulant tubes
and centrifuged at 960 g for 10 minutes. Nucleated cells
were separated and frozen at −80°C until use. Genomic
DNA was extracted from 100μL aliquots of frozen cells
with the EZ-DNA extraction kit (Biological IndustriesW,
Kibbutz Beit Haemek, Israel), according to manufacturer
instructions.
Patients’ and controls’ HLA Class I (A, B) and Class II
(DRB1) genotypes were determined by the reverse dot blot
PCR-SSO method, using the commercially available RELI™
SSO kit (DYNAL BIOTECH A.S.A, Oslo, Norway). Geno-
typing was performed at the Immunogenetic Laboratory
of the State University of Maringá.
Statistical analysis
A data bank of HLA-A, -B and –DRB1 processing re-
sults was created in Microsoft Excel 2007. Data were
expressed as allele frequency (F), calculated as the ratio
of the number of times different alleles appeared in the
sample to the total number of alleles. The P-value was
calculated using a two-tailed Fisher’s exact test at a 5%
significance level. Significant P-values were corrected
with the Bonferroni method (Pc) by multiplying P by the
number of alleles detected for each locus. Again, Pc
values <0.05 were considered significant. Odds ratios
(OR) at a 95% confidence interval (CI) were calculated
for results with P < 0.05. Whereas descriptive statistical
analyses for sex and ethnicity variables were determined
by Fisher’s exact test, the age variable was calculated with
the t-test for independent samples, also with a significance
level of 5%. Statistical analyses were performed in the
R and Statistica 7.0 software packages. Arlequin 2000
http://cmpg.unibe.ch/software/arlequin3/ was employed to
confirm the distribution of allele frequency and P > 0.05
rates were in Hardy–Weinberg equilibrium (HW). Haplo-
type frequencies were estimated using the Expectation
Maximization (EM) algorithm included in the Arlequin
software.
Results
The present study investigated a potential association
between ACL and Class I and Class II HLA alleles in a
Southern Brazilian population by comparing the fre-
quency of HLA-A, HLA-B and HLA-DRB1 alleles in
Figure 1 Composition of groups and subgroups comprising ACL group (n=169).
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subjects affected by the disease and those of healthy
controls.
The distribution of allele proportions reported is in HW
equilibrium both in the patient group and in the control one.
ACL overall versus control group
Table 1 shows the HLA-A, HLA-B and HLA-DRB1 allele
frequencies of the group. Overall, there were differences
between ACL patients and the control group for allele
HLA-B*45, which was more frequent in the control group
[0% vs. 2.31% (P = 0.0046 and Pc = 0.1426)], with a trend
towards resistance to ACL development. The presence of
HLA-DRB1*13 in the ACL and control groups [15.1% vs.
10.38% (P = 0.0431; Pc = 0.6465; OR = 1.5335; 95%CI =
1.0177 – 2.3107)] suggested a trend towards ACL
susceptibility.
Table 1 Frequency of HLA-A, -B and -DRB1 alleles in the ACL group versus the control group
ACL (n = 169) Controls
(n = 260)
ACL (n = 169) Controls
(n = 260)
Allele n F % n F % P-value Pc-value OR 95%CI Allele n F% n F% P-value Pc-value OR 95%CI
HLA – A* HLA-B*
01 37 10.9 47 9.0 ns - 07 20 5.9 38 7.3 ns -
02 95 28.1 127 24.4 ns - 08 16 4.7 34 6.5 ns -
03 30 8.8 56 10.8 ns - 13 1 0.3 9 1.7 ns -
11 23 6.8 26 5.0 ns - 14 15 4.4 22 4.2 ns -
23 18 5.3 22 4.2 ns - 15 26 7.7 48 9.2 ns -
24 37 10.9 62 11.9 ns - 18 17 5.0 36 6.9 ns -
25 4 1.2 13 2.5 ns - 27 7 2.1 8 1.5 ns -
26 11 3.2 18 3.5 ns - 35 58 17.2 68 13.1 ns -
29 9 2.6 28 5.4 ns - 37 1 0.3 5 1.0 ns -
30 11 3.2 25 4.8 ns - 38 10 3.0 15 2.9 ns -
31 18 5.3 19 3.7 ns - 39 13 3.9 18 3.5 ns -
32 8 2.3 16 3.1 ns - 40 18 5.3 16 3.1 ns -
33 5 1.5 15 2.9 ns - 41 2 0.6 6 1.2 ns -
34 3 0.9 5 1.0 ns - 42 2 0.6 6 1.2 ns -
36 2 0.6 2 0.4 ns - 44 43 12.7 46 8.9 ns -
39 1 0.3 - - ns - 45 0 - 12 2.3 0.0046 0.1426 - -
66 3 0.9 1 0.2 ns - 46 0 - 4 0.8 ns -
68 19 5.62 35 6.7 ns - 47 0 - 1 0.2 ns -
74 4 1.9 3 0.6 ns - 48 3 0.9 2 0.4 ns -
HLA-DRB1* 49 8 2.4 8 1.5 ns -
01 23 6.8 42 8.1 ns - 50 8 2.4 14 2.7 ns -
03 32 9.5 61 11.7 ns - 51 29 8.6 44 8.5 ns -
04 40 11.8 56 10.8 ns - 52 10 3.0 11 2.1 ns -
07 39 11.5 67 12.9 ns - 53 7 2.1 8 1.5 ns -
08 26 7.7 30 5.8 ns - 54 1 0.3 3 0.6 ns -
09 4 1.2 4 0.8 ns - 55 8 2.4 12 2.3 ns -
10 5 1.5 10 1.9 ns - 56 2 0.6 1 0.2 ns -
11 45 13.3 81 15.6 ns - 57 7 2.1 12 2.3 ns -
12 3 0.9 10 1.9 ns - 58 6 1.8 10 1.9 ns -
13 51 15.1 54 10.4 0.0431 0.6465 1.53 1.01-2.31 73 0 - 1 0.2 ns -
14 19 5.6 40 7.7 ns - 81 0 - 2 3.9 ns -
15 34 10.1 44 8.8 ns -
16 17 5.0 21 4.0 ns -
n = number of times the allele occurs; F = allele frequency; P-value = calculated by Fisher’s exact test; Pc-value = value of p corrected by Bonferroni correction; OR
= odds ratio; 95%CI = 95% confidence interval; ns= not significant (p > 0.05).
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Haplotype analysis revealed frequency of 772 haplo-
types in the ACL group and 1118 in the control group.
Only haplotypes whose frequencies appeared to differ
between groups (17 haplotypes) were analyzed. There
were statistical differences between patients with ACL
and controls for the haplotypes A*02 B*44 DRB1*07
(2.37% vs. 0% [P = 0.0236]) and A*24 B*35 DRB1*01
(2.37% vs. 0% [P = 0.0236]). Thus, these two haplotypes
may be involved in susceptibility to ACL (Table 2).
Group 1 versus control group
Table 3 shows a comparison of HLA-A, HLA-B and
HLA-DRB1 allele frequencies between Group 1 and the
control group. Differences exist between Group 1 and
the control group for HLA-B*35, which was more fre-
quent in patients [19.5% vs. 13.1% (P = 0.0218; Pc =
0.6758; OR = 1.6086; 95%CI = 1.0851 – 2.3848), and
HLA-B*44 [13.9% vs. 8.8% (P = 0.0290; Pc = 0.8990; OR =
1.6734; 95%CI = 1.0592 – 2.6436), which suggests suscep-
tibility to the cutaneous form of ACL. HLA-B*45 was only
present in controls [0% vs. 2.31% (P = 0.0107; Pc =
0.3317)], which suggests that it may confer resistance to
the cutaneous form of ACL. Moreover, comparison of
HLA-DRB1*13 frequency in group 1 versus controls
[16.2% vs. 10.4% (P = 0.0228; Pc = 0.3420; OR = 1.6654;
95%CI = 1.0851 – 2.5561) indicated a possible susceptibil-
ity to the cutaneous form of ACL.
Subgroup 1A versus control group
Table 4 shows HLA-A, HLA-B and HLA-DRB1 allele fre-
quencies in subgroup 1A and the control group. When al-
lele frequencies were compared between group 1A and
the control group, HLA-B*44 [14.8% vs. 8.8% (P = 0.0160;
Pc = 0.4960; OR = 1.7943; 95%CI = 1.1219 – 2.8696)] sug-
gested a possible susceptibility to the cutaneous form of
ACL. On the other hand, HLA-B*45 [0% vs., 2.31% (P =
0.0225; Pc = 0.6975) suggested possible resistance to the
cutaneous form of ACL. HLA-DRB1*13 [16.10% vs.
10.38% (P = 0.0152; Pc = 0.2280; OR = 1.6562; 95%CI =
1.0591 – 2.5899) may also be involved in susceptibility to
the cutaneous form of ACL.
Preliminary results from the other groups and subgroups
versus the control group
Analysis of allele frequencies in subgroups 1B, 2A, 3A
and group 3 versus the control group did not reveal
any statistically significant differences in the HLA loci
studied.
Comparison between group 2 and the control group
showed that HLA-B*27 allele was more frequent in
group 2 subjects (10.0% vs. 1.5% [P = 0.0180; Pc =
0.5580; OR = 7.1111; 95%CI = 1.7850 – 28.3286]) indi-
cating a possible susceptibility to mucocutaneous ACL.
Furthermore, the HLA-B*27 allele was more frequent in
patients of subgroup 2B (25.0% vs. 1.5% [P = 0.0085; Pc =
0.2635; OR = 21.3333; IC 95% = 3.7218 - 122.2835]),
suggesting susceptibility to mucocutaneous ACL.
HLA-A*01 was more frequent in patients from sub-
group 3B (28.6% vs. 9% [P = 0.0360; Pc = 0.6480; OR =
4.0255; 95%CI = 1.2153 – 13.3341]), as was HLA-B*52
(21.4% vs. 2.1% [P = 0.0044; Pc = 0.1364; OR = 12.6198;
95%CI = 3.0827 – 51.6619]), suggesting possible suscep-
tibility to relapse of cutaneous ACL at a location remote
from the site of previous infection.
HLA-B*49 was more frequent in group 4 patients than
in controls (9.1% vs. 1.5% [P = 0.0101; Pc = 0.3131; OR =
6.4000; 95%CI = 1.8472 – 22.1743]), indicating susceptibil-
ity to recurrent ACL.
After correction of P-values, we could not detect any
association between susceptibility to or protection
against ACL within the allele frequencies of MHC class I
(HLA-A and HLA-B) and class II (HLA-DRB1) genetic
markers among the several the patient and control
groups and subgroups analyzed in this study. Table 5
shows all alleles with trends toward increased suscepti-
bility and/or resistance to ACL in these groups and
subgroups.
Discussion
One of the first studies assessing the potential associ-
ation between HLA and cutaneous leishmaniasis involv-
ing serological methods was undertaken in France, with
L. guyanensis. The study revealed a low HLA-Cw7 fre-
quency was associated with pathogenesis of cutaneous
leishmaniasis [16]. A Mexican study involving L.
mexicana was undertaken by the molecular biology
method, with 65 cases of cutaneous leishmaniasis and
100 controls. Whereas the frequencies of two alleles
were associated with the protection against cutaneous
leishmaniasis, namely HLA-DR2 (OR = 0.15; 95%CI =
0.05 – 0.38; P = 0.0000018) and HLA-DPB1*0401 (OR =
0.37; 95%CI = 0.21 – 0.67; P = 0.0004), two others were
Table 2 Frequency of HLA-A/-B/–DRB1 haplotypes in the ACL group versus the control group
Haplotypes Frequency (%)
Controls (n=260) ACL (n=169) P-value OR (95%CI)
HLA-A*02-B*44-DRB1*07 0 (0.00%) 4 (2.37%) 0.0236 -
HLA-A*24-B*35-DRB1*01 0 (0.00%) 4 (2.37%) 0.0236 -
P-value obtained by Fisher's exact test. Of all analyzed haplotypes, only those having P-values <0.05 were added to this table.
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Allele n F % n F % P-value Pc-value OR 95%CI Allele n F % n F% P-value Pc–value OR 95%CI
HLA – A* HLA-B*
01 29 10.7 47 9.0 ns - 07 15 5.5 38 7.3 ns -
02 73 26.8 127 24.4 ns - 08 10 3.7 34 6.5 ns -
03 24 8.8 56 10.8 ns - 13 1 0.4 9 1.7 ns -
11 18 6.6 26 5.0 ns - 14 14 5.2 22 4.2 ns -
23 14 5.2 22 4.2 ns - 15 23 8.5 48 9.2 ns -
24 28 10.3 62 11.9 ns - 18 13 4.8 36 6.9 ns -
25 4 1.5 13 2.5 ns - 27 3 1.1 8 1.5 ns -
26 8 2.9 18 3.5 ns - 35 53 19.5 68 13.1 0.0218 0.6758 1.67 1.08-2.29
29 9 3.3 28 5.4 ns - 37 1 0.4 5 1.0 ns -
30 9 3.3 25 4.8 ns - 38 7 2.6 15 2.9 ns -
31 15 5.5 19 3.7 ns - 39 10 3.7 18 3.5 ns -
32 7 2.6 16 3.1 ns - 40 14 5.2 16 3.1 ns -
33 5 1.8 15 2.9 ns - 41 2 0.7 6 1.2 ns -
34 3 1.1 5 1.0 ns - 42 2 0.7 6 1.2 ns -
36 1 0.4 2 0.4 ns - 44 38 14.0 46 8.9 0.0290 0.8990 1.67 1.05-2.64
39 1 0.4 - - ns - 45 0 - 12 2.3 0.0107 0.3317 - -
66 2 0.7 1 0.2 ns - 46 0 - 4 0.8 ns -
68 19 7.0 35 6.7 ns - 47 0 - 1 0.2 ns -
74 3 1.1 3 0.6 ns - 48 3 1.1 2 0.4 ns -
HLA-DRB1* 49 4 1.5 8 1.5 ns -
01 18 6.6 42 8.1 ns - 50 6 2.2 14 2.7 ns -
03 22 8.1 61 11.7 ns - 51 24 8.8 44 8.5 ns -
04 33 12.1 56 10.8 ns - 52 6 2.2 11 2.1 ns -
07 33 12.1 67 12.9 ns - 53 7 2.6 8 1.5 ns -
08 20 7.4 30 5.8 ns - 54 0 - 3 0.6 ns -
09 4 1.5 4 0.8 ns - 55 5 1.8 12 2.3 ns -
10 5 1.8 10 1.9 ns - 56 1 0.3 1 0.2 ns -
11 33 12.1 81 15.6 ns - 57 5 1.8 12 2.3 ns -



















Table 3 Frequency of HLA-A, -B and –DRB1 alleles in ACL Group 1 and the control group (Continued)
13 44 16.2 54 10.4 0.0228 0.3420 1.66 1.08-2.55 73 0 - 1 0.2 ns -
14 14 5.2 40 7.7 ns - 81 0 - 2 3.9 ns -
15 28 10.3 44 8.8 ns -
16 15 5.5 21 4.0 ns -
n = number of times the allele occurs; F = allele frequency; P-value = calculated by Fisher’s exact test; Pc-value = value of P corrected by Bonferroni correction; OR = odds ratio; 95%CI = 95% confidence interval; ns=



























Allele n F % n F % P-value Pc-value OR 95%CI Allele n F % n F % P-value Pc-value OR 95%CI
HLA – A* HLA-B*
01 26 11.0 47 9.0 ns - 07 14 5.9 38 7.3 ns -
02 64 27.1 127 24.4 ns - 08 10 4.2 34 6.5 ns -
03 21 8.9 56 10.8 ns - 14 10 4.2 22 4.2 ns -
11 16 6.8 26 5.0 ns - 15 22 9.3 48 9.2 ns -
24 24 10.2 62 11.9 ns - 18 10 4.2 36 6.9 ns -
HLA-DRB1* 27 3 1.3 8 1.5 ns -
01 16 6.8 42 8.1 ns 35 44 18.6 68 13.1 ns -
03 20 8.4 61 11.7 ns - 39 8 3.4 18 3.5 ns -
04 27 11.4 56 10.8 ns - 40 12 5.1 16 3.1 ns -
07 29 12.3 67 12.9 ns - 44 35 14.8 46 8.9 0.0160 0.4969 1.79 1.12-2.87
08 17 7.2 30 5.8 ns - 45 0 - 12 2.3 0.0231 0.0225 - -
11 31 13.1 81 15.6 ns - 49 3 1.3 8 1.5 ns -
13 38 16.1 54 10.4 0.0152 0.2280 1.65 1.06-2.59 51 20 8.5 44 8.5 ns -
14 11 4.7 40 7.7 ns 52 6 2.5 11 2.1 ns -
15 24 10.2 44 8.8 ns -
n = number of times the allele occurs; F = allele frequency; P-value = calculated by Fisher’s exact test; Pc-value = value of P corrected by Bonferroni correction; OR = odds ratio; 95%CI = 95% confidence interval; ns=



















associated with increased susceptibility: HLA-DRB1
*0407 (OR = 2.14; 95%CI = 1.34 – 3.40; P = 0.001) and
HLA-DPA1*0401 (OR = 10.77; 95%CI = 1.25 – 80.73;
P = 0.003) [20].
There have been few Brazilian studies on the associ-
ation between HLA and susceptibility to/protection from
cutaneous and mucocutaneous leishmaniasis [16-19],
and there is no evidence of any studies in the literature
addressing the association between HLA and ACL
caused by L. braziliensis in the northwestern region of
Paraná, southern Brazil. Studies of the association be-
tween HLA and visceral leishmaniasis are underway
[20,21]; however, this is another form of the disease
caused by another Leishmania species and presenting
with different clinical manifestations. Thus, we chose
not to compare the genetic markers found in these sur-
veys with the results of the present study.
A serological study in Brazil involving L. braziliensis
found that allele HLA-DQw3 was associated with risk of
infection and HLA-DR2 was associated with protection
(Pc = 0.004; RR = 0.007) against mucocutaneous leish-
maniasis [18]. The present investigation found no associ-
ations with HLA-DR2 in any group.
Preliminary results of the allele frequency of HLA-B*27
(P = 0.0180, Pc = 0.5580) showed a trend toward suscepti-
bility to ACL among patients with the mucocutaneous
form. Although the patient samples were too small to
draw any definitive conclusions, this finding corroborates
that of Petzl-Erler et al. (1991), who analyzed 43 subjects
with mucocutaneous leishmaniasis and compared them
with 111 controls and initially found the HLA-B27 to be
significantly associated (P = 0.029), but the significance
did not hold after P-value correction.
Allele frequency of HLA-DRB1*13 (P = 0.0228, Pc =
0.3317) was conspicuous only in the non-recurrent cuta-
neous leishmaniasis groups, whereas HLA-B*49 was
prominent in the recurrent disease group.
Studies have shown that CD4 + T lymphocytes of the
Th1 type play a more important role in the immune re-
sponse to mucosal disease, as there is a major predomin-
ance of CD8+ T lymphocytes in mucocutaneous lesions
caused by L. braziliensis [22,23]. The present study has
detected a trend toward association with an MHC class I
allele (HLA-B*27) in patients with mucocutaneous leish-
maniasis, which presents parasite antigens for CD8+
lymphocytes T. It may thus be surmised that a role of
CD8+ T lymphocytes in mucocutaneous leishmaniasis
cannot be ruled out.
An immunocytochemical study conducted in the
Amazon region found that CD8+ T cells occurred at a
higher level in all forms of the disease except mucocuta-
neous leishmaniasis, and included cases of cutaneous le-
sions caused by L. braziliensis. Its results seem to
corroborate the role of CD8+ T cells in a balanced
Table 5 Contribution of Class I and II HLA alleles to development of ACL in a Southern Brazilian population
Allele
ACL Controls (n = 260) P-value Pc-value OR 95%CI
n F % n F %
ACL overall (n = 169)
HLA-B*45 0 - 12 2.3 0.0046 0.1426 - -
HLA-DRB1*13 51 15.1 54 10.4 0.0431 0.6465 1.53 1.01-2.31
ACL (group 1; n = 136)
HLA-DRB1*13 44 16.2 54 10.4 0.0228 0.3420 1.66 1.08-2.55
HLA-B*35 53 19.5 68 13.1 0.0218 0.6758 1.67 1.08-2.29
HLA-B*44 38 14.0 46 8.9 0.0290 0.8990 1.67 1.05-2.64
HLA-B*45 0 - 12 2.3 0.0107 0.3317 - -
ACL (group 1A; n = 118)
HLA-B*44 35 14.8 46 8.9 0.0160 0.4969 1.79 1.12-2.87
HLA-B*45 0 - 12 2.3 0.0231 0.0225 - -
HLA-DRB1*13 38 16.1 54 10.4 0.0152 0.2280 1.65 1.06-2.59
ACL (group 2; n = 15)
HLA-B*27 3 10.0 8 1.5 0.0180 0.5580 7.11 1.78-28.33
ACL (group 3B; n = 7)
HLA-B*52 3 21.4 11 2.1 0.0044 0.1360 12.61 3.08-51.66
ACL (group 4; n = 22)
HLA-B*49 4 9.1 8 1.5 0.0101 0.3131 6.4 1.8-22.17
n = number of times the allele occurs; F = Allele frequency; P-value = calculated by Fisher’s exact test; Pc-value = value of P corrected by Bonferroni correction;
OR = odds ratio; 95%CI = 95% confidence interval.
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immune response to cutaneous lesions and, probably, in
the healing process [23]. In the present study, HLA-B*45
was the only allele associated with a trend toward pro-
tection from cutaneous lesions. This corroborates the
findings of Silveira et al., 2004, who endorse the role of
CD8+ T lymphocytes in the healing of cutaneous le-
sions. Furthermore, HLA-B*45 involvement suggests
that the common sequence for the antigen group may
anchor parasite peptides and trigger a protecting re-
sponse. It bears noting that HLA-B*45 is a rare allele in
Brazilian populations, with frequencies ranging from 1.0 %
to 1.6% in the state of Paraná [24]. However, its frequency
in the control and patient groups was 2.3% and 0% re-
spectively. Special attention should be given to this allele
in ACL studies.
The frequency of the HLA-A*02-B*44-DRB1*07 and
HLA-A*24-B*35-DRB1*01 haplotypes may be involved
in susceptibility to cutaneous leishmaniasis. There is evi-
dence in the literature of the involvement of these hap-
lotypes with ACL. Studies have shown occurrence of the
HLA-A*02-B*44-DRB1*07 haplotype in populations in
the Brazilian states of Maranhão and even in the north
of Paraná [25,26].
Research on the epidemiological profiles of ACL shows
that infected patients are predominantly male [7,27]. Al-
though the present study did find a male predominance
in the infected group, no significant difference between
the sexes was found in the control group. Even though
males and females are exposed to the same environmen-
tal risk factors necessary for ACL acquisition, males are
infected with the parasite much more often. The infre-
quency of ACL in females may be due to their use of re-
pellents to protect themselves during the day and to
their relatively infrequent exposure to risk factors, such
as being near rivers and in the woods, as compared with
men. Furthermore, the sample collection period for the
control group may have influenced the number of
women in the control group, as women were more likely
than men to be home in the morning and afternoon.
In the present study, analysis of MHC class I (HLA-A
and HLA-B) and class II (HLA-DRB1) genetic markers
failed to show any association with susceptibility or pro-
tection to ACL after P-value correction. However, all re-
sults which initially had significant P-values should be
carefully observed in further studies, and future studies
be conducted with other markers. It bears stressing that,
despite the very small sample size of some groups, our
findings demonstrate that associations may, in fact, exist
between HLA alleles and ACL, and that studies with lar-
ger sample sizes are warranted.
Conclusions
Since the Brazilian population is highly miscegenated,
results from studies undertaken in a single region should
not be generalized to the whole country. Populations of
several other regions should be researched and their al-
lele diversity analyzed so that new associations can be
identified or those already known corroborated. Such
knowledge shall contribute towards future prophylactic
and therapeutic interventions in Brazilian groups at
higher risk of developing ACL.
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